You are here

Yervoy

Most-clicked pharma news for week ending March 18 2023: Medtronic offers early retirement package, Novartis to sell ophthalmological assets, and Pfizer tops list of drugs with price increases

Most-clicked pharma news for week ending March 18 2023: Medtronic offers early retirement package, Novartis to sell ophthalmological assets, and Pfizer tops list of drugs with price increases

CP WIre

Bristol Myers Squibb

executive compensation

Flag link:

Most-clicked pharma news for week ending March 18 2023: Medtronic offers early retirement package, Novartis to sell ophthalmological assets, and Pfizer tops list of drugs with price increases

Bristol Myers Squibb

executive compensation

Flag link:

Bristol Myers doubles down in immuno-oncology patent fight with AZ, this time targeting Imjudo

Bristol Myers doubles down in immuno-oncology patent fight with AZ, this time targeting Imjudo

Fierce Pharma

Bristol Myers Squibb

Flag link:

Regeneron's Libtayo posts lung cancer win with Bristol's Yervoy. But company won't seek approval

Regeneron's Libtayo posts lung cancer win with Bristol's Yervoy. But company won't seek approval

Fierce Pharma

non-small cell lung cancer

Bristol Myers Squibb

Flag link:

ESMO: Bristol Myers, Roche fail in post-surgery kidney cancer. But is it good news for Merck's Keytruda?

ESMO: Bristol Myers, Roche fail in post-surgery kidney cancer. But is it good news for Merck's Keytruda?

Fierce Pharma

Bristol Myers Squibb

Flag link:

Exelixis trot out Opdivo-Yervoy-Cabometyx combo win in kidney cancer. Will FDA accept?

Exelixis trot out Opdivo-Yervoy-Cabometyx combo win in kidney cancer. Will FDA accept?

Fierce Pharma

Bristol Myers Squibb

Flag link:

ESMO: Facing new Keytruda combos from Merck, BMS touts 5-year kidney cancer data for Opdivo-Yervoy

ESMO: Facing new Keytruda combos from Merck, BMS touts 5-year kidney cancer data for Opdivo-Yervoy

Fierce Pharma

Bristol Myers Squibb

Flag link:

Bristol Myers rolls out 3-year data mesothelioma data for Opdivo/Yervoy in first look at ESMO slate

Bristol Myers rolls out 3-year data mesothelioma data for Opdivo/Yervoy in first look at ESMO slate

Endpoints

Bristol Myers Squibb

Flag link:

Xilio raises $95M to take twists on Yervoy and IL-2 into clinic

Xilio raises $95M to take twists on Yervoy and IL-2 into clinic

Fierce Biotech

Xilio Therapeutics

clinical trials

Flag link:

Merck's Keytruda Proves Better Alone in Combination Trial With BMS' Yervoy

Merck's Keytruda Proves Better Alone in Combination Trial With BMS' Yervoy

BioSpace

Bristol-Myers Squibb

non-small cell lung cancer

Flag link:

WCLC: With Keytruda-Yervoy data, Merck casts doubt on Opdivo's place in lung cancer

WCLC: With Keytruda-Yervoy data, Merck casts doubt on Opdivo's place in lung cancer

Fierce Pharma

Bristol-Myers Squibb

Flag link:

Merck pulls the plug on a study evaluating blockbuster Keytruda with Yervoy for NSCLC

Merck pulls the plug on a study evaluating blockbuster Keytruda with Yervoy for NSCLC

Endpoints

clinical trials

non-small cell lung cancer

Flag link:

Jounce shares crash after it abandons immunotherapy combination trial

Jounce shares crash after it abandons immunotherapy combination trial

Pharmaforum

Jounce Therapeutics

non-small cell lung cancer

Bristol-Myers Squibb

Flag link:

Bristol Myers Squibb Drug Combination Wins FDA Approval for Mesothelioma

Bristol Myers Squibb Drug Combination Wins FDA Approval for Mesothelioma

Motley Fool

Bristol-Myers Squibb

Flag link:

Bristol Myers' Opdivo-Yervoy duo slashes mesothelioma death risk by 26%

Bristol Myers' Opdivo-Yervoy duo slashes mesothelioma death risk by 26%

Fierce Pharma

Bristol-Myers Squibb

clinical trials

Flag link:

I-O blockbusters from Merck, BMS and more linked to poor COVID-19 outcomes: study

I-O blockbusters from Merck, BMS and more linked to poor COVID-19 outcomes: study

Fierce Pharma

immuno-oncology

checkpoint inhibitors

Bristol-Meyers Squibb

Flag link:

FDA approval tracker: several early decisions in May

FDA approval tracker: several early decisions in May

EP Vantage

Blueprint Medicines

Bristol-Myers Squibb

Flag link:

FDA approves Opdivo + Yervoy combined with limited chemotherapy as first-line treatment of metastatic or recurrent NSCLC

FDA approves Opdivo + Yervoy combined with limited chemotherapy as first-line treatment of metastatic or recurrent NSCLC

Pharmaceutical Business Review

Bristol-Myers Squibb

metastatic non-small cell lung cancer

Flag link:

Ahead of ASCO, Bristol Myers Squibb Announces Results for Three Clinical Trials

Ahead of ASCO, Bristol Myers Squibb Announces Results for Three Clinical Trials

BioSpace

Bristol-Myers Squibb

non-small cell lung cancer

Multiple Myeloma

Flag link:

ASCO 2020 – first-line lung cancer focus

ASCO 2020 – first-line lung cancer focus

EP Vantage

Bristol-Myers Squibb

Flag link:

Pages